Abstract
The search for newer histone deacetylase (HDAC) inhibitors has attracted a great deal of interest of medicinal chemists worldwide, especially after the first HDAC inhibitor (Zolinza®, widely known as SAHA or Suberoylanilide hydroxamic acid) was approved by the FDA for the treatment of Tcell lymphoma in 2006. As a continuity of our ongoing research in this area, we designed and synthesized a series of 5-aryl-1,3,4-thiadiazole-based hydroxamic acids as analogues of SAHA and evaluated their biological activities. Most of the compounds in this series, e.g. compounds with 5-aryl moiety being 2- furfuryl (5a), 5-bromofuran-2-yl (5b), 5-methylfuran-2-yl (5c), thiophen-2-yl (5d), 5-methylthiophen-2-yl (5f) and pyridyl (5g-i), were found to have potent anticancer cytotoxicity with IC50 values of generally 5- to 10-fold lower than that of SAHA in 4 human cancer cell lines assayed. Those compounds with potent cytotoxicity were also found to have strong HDAC inhibition effects. Docking studies revealed that compounds 5a and 5d displayed high affinities towards HDAC2 and 8.
Keywords: Histone deacetylase (HDAC) inhibitors, 5-aryl-1, 3, 4-thiadiazole, cytotoxicity, heterocycle.
Graphical Abstract
Medicinal Chemistry
Title:5-Aryl-1,3,4-Thiadiazole-Based Hydroxamic Acids as Histone Deacetylase Inhibitors and Antitumor Agents: Synthesis, Bioevaluation and Docking Study
Volume: 11 Issue: 3
Author(s): Tran Thi Lan Huong, Do Thi Mai Dung, Dao Thi Kim Oanh, Tran Thi Bich Lan, Phan Thi Phuong Dung, Vu Duc Loi, Kyung Rok Kim, Byung Woo Han, Jieun Yun, Jong Soon Kang, Youngsoo Kim, Sang-Bae Han and Nguyen-Hai Nam
Affiliation:
Keywords: Histone deacetylase (HDAC) inhibitors, 5-aryl-1, 3, 4-thiadiazole, cytotoxicity, heterocycle.
Abstract: The search for newer histone deacetylase (HDAC) inhibitors has attracted a great deal of interest of medicinal chemists worldwide, especially after the first HDAC inhibitor (Zolinza®, widely known as SAHA or Suberoylanilide hydroxamic acid) was approved by the FDA for the treatment of Tcell lymphoma in 2006. As a continuity of our ongoing research in this area, we designed and synthesized a series of 5-aryl-1,3,4-thiadiazole-based hydroxamic acids as analogues of SAHA and evaluated their biological activities. Most of the compounds in this series, e.g. compounds with 5-aryl moiety being 2- furfuryl (5a), 5-bromofuran-2-yl (5b), 5-methylfuran-2-yl (5c), thiophen-2-yl (5d), 5-methylthiophen-2-yl (5f) and pyridyl (5g-i), were found to have potent anticancer cytotoxicity with IC50 values of generally 5- to 10-fold lower than that of SAHA in 4 human cancer cell lines assayed. Those compounds with potent cytotoxicity were also found to have strong HDAC inhibition effects. Docking studies revealed that compounds 5a and 5d displayed high affinities towards HDAC2 and 8.
Export Options
About this article
Cite this article as:
Huong Thi Lan Tran, Dung Thi Mai Do, Oanh Thi Kim Dao, Lan Thi Bich Tran, Dung Thi Phuong Phan, Loi Vu Duc, Kim Rok Kyung, Han Woo Byung, Yun Jieun, Kang Soon Jong, Kim Youngsoo, Han Sang-Bae and Nam Nguyen-Hai, 5-Aryl-1,3,4-Thiadiazole-Based Hydroxamic Acids as Histone Deacetylase Inhibitors and Antitumor Agents: Synthesis, Bioevaluation and Docking Study , Medicinal Chemistry 2015; 11 (3) . https://dx.doi.org/10.2174/1573406410666140925153128
DOI https://dx.doi.org/10.2174/1573406410666140925153128 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Phospholipase A2 Receptor Autoantibody: A New Biomarker for Primary Membranous Nephropathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) An Insight into the Dermatological Applications of Neem: A Review on Traditional and Modern Aspect
Recent Advances in Anti-Infective Drug Discovery Non-Alcoholic Fatty Pancreas Disease (NAFPD): A Silent Spectator or the Fifth Component of Metabolic Syndrome? A Literature Review
Endocrine, Metabolic & Immune Disorders - Drug Targets The NK-1 Receptor: A New Target in Cancer Therapy
Current Drug Targets Role of Inhibitory BCR Co-Receptors in Immunity
Infectious Disorders - Drug Targets Targeting CFTR: How to Treat Cystic Fibrosis by CFTR-Repairing Therapies
Current Drug Targets Energy Balance and Carcinogenesis: Underlying Pathways and Targets for Intervention
Current Cancer Drug Targets Optimizing Gene Silencing Strategies for Pancreatic Cancer
Current Cancer Therapy Reviews Novel Therapeutic Approaches in Pancreatic Cancer Based on Genomic Alterations
Current Pharmaceutical Design Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets Marine Derived Anticancer Drugs Targeting Microtubule
Recent Patents on Anti-Cancer Drug Discovery Nutritional Aspects Relating to the Developmental Origins of Health and Disease
Current Women`s Health Reviews Targeting SUMOylation Cascade for Diabetes Management
Current Drug Targets The Endocrine Regulation of Stem Cells: Physiological Importance and Pharmacological Potentials for Cell-Based Therapy
Current Stem Cell Research & Therapy Cross Talk between the Cardiovascular and Nervous Systems:Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development
Current Pharmaceutical Design Biomedical Applications of Accelerator Mass Spectrometry
Current Analytical Chemistry DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) A New Antitumor Agent, (3-chloro-7-methoxyfuro[2,3-b]-quinolin-4-yl)-(4-methoxyphenyl) amine, Loaded in Solid Lipid Nanoparticles: Characterization and Pharmacokinetics
Current Nanoscience Is Technical-Grade Chlordane an Obesogen?
Current Medicinal Chemistry Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications
Current Drug Targets